Return to Today's science sparks archives

2020-07-01

Fig 1. Domain architecture of the NLRP1 inflammasome proteins.

Fig 1. Domain architecture of the NLRP1 inflammasome proteins.
  • Taabazuing CY, Griswold AR, Bachovchin DA

  • Immunol Rev. 2020 Jun 19. doi: 10.1111/imr.12884.
Open Access button

2020-07-02

Supplemental Fig S1. Procedure for evaluation of the performance of the method using light and stable isotopically heavy-labeled λ Ig (SILuMAb).

Supplemental Fig S1. Procedure for evaluation of the performance of the method using light and stable isotopically heavy-labeled λ Ig (SILuMAb).
  • Martins CO, Huet S, Yi SS, Ritorto MS, Landgren O, Dogan A, Chapman JR

  • J Mol Diagn. 2020 Jul;22(7):901-911. doi: 10.1016/j.jmoldx.2020.04.002. Epub 2020 Apr 14.

2020-07-06

Fig 1. Total Body Mass vs. Leptin.

Fig 1. Total Body Mass vs. Leptin.
  • Downs, M.E.,Scott, J.M.,Ploutz-Snyder, L.L.,Ploutz-Snyder, R.,Goetchius, E., Buxton, R.E., Danesi, C.P., Randolph, K.M., Urban, R.J., Sheffield-Moore, M., Dillon, E.L.

  • Life Sciences in Space Research. 2020 Aug;26:97-104. doi: 10.1016/j.lssr.2020.03.008

2020-07-07

FIG A1. Data dictionary.

FIG A1. Data dictionary.
  • Daly B, Gorenshteyn D, Nicholas KJ, Zervoudakis A, Sokolowski S, Perry CE, Gazit L, Baldwin Medsker A, Salvaggio R, Adams L, Xiao H, Chiu YO, Katzen LL, Rozenshteyn M, Reidy-Lagunes DL, Simon BA, Perchick W, Wagner I

  • JCO Clin Cancer Inform. 2020 Mar;4:275-289. doi: 10.1200/CCI.19.00104.
Open Access button

2020-07-08

Figure 2. Representative immunohistochemical maspin protein stains showing four different TMA cores.

Figure 2. Representative immunohistochemical maspin protein stains showing four different TMA cores.
  • Tanaka A, Wang JY, Shia J, Zhou Y, Ogawa M, Hendrickson RC, Klimstra DS, Roehrl MHA

  • Front Oncol. 2020 Jun 10;10:945. doi: 10.3389/fonc.2020.00945. eCollection 2020.
Open Access button

2020-07-09

Figure 3. Allogeneic T cells induce cell death in intestinal organoids with autophagy gene mutations.

Figure 3. Allogeneic T cells induce cell death in intestinal organoids with autophagy gene mutations.
  • Matsuzawa-Ishimoto Y, Hine A, Shono Y, Rudensky E, Lazrak A, Yeung F, Neil JA, Yao X, Chen YH, Heaney T, Schuster SL, Zwack EE, Axelrad JE, Hudesman D, Tsai JJ, Nichols K, Dewan MZ, Cammer M, Beal A, Hoffman S, Geddes B, Bertin J, Liu C, Torres VJ, Loke P, van den Brink MRM, Cadwell K

  • Blood. 2020 Jun 25;135(26):2388-2401. doi: 10.1182/blood.2019004116.

2020-07-10

Figure 1. COVID-19 in patients with lung cancers.

Figure 1. COVID-19 in patients with lung cancers.
  • Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, McCarthy CG, Falcon CJ, Schoenfeld AJ, Arbour KC, Chaft JE, Daly RM, Drilon A, Eng J, Iqbal A, Lai WV, Li BT, Lito P, Namakydoust A, Ng K, Offin M, Paik PK, Riely GJ, Rudin CM, Yu HA, Zauderer MG, Donoghue MTA, Luksza M, Greenbaum BD, Kris MG, Hellmann MD

  • Ann Oncol. 2020 Jun 16. pii: S0923-7534(20)39894-X. doi: 10.1016/j.annonc.2020.06.007.
Open Access button

2020-07-13

Figure 1 Swimmer plot of patients with mUM treated with ipilimumab +nivolumab.

Figure 1 Swimmer plot of patients with mUM treated with ipilimumab +nivolumab.
  • Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, Durden B, Eroglu Z, Bhatia S, Park S, Chowdhary A, Chandra S, Kennedy J, Ernstoff M, Vachhani P, Drabick J, Singh A, Xu T, Yang J, Carvajal R, Manson D, M Kirkwood J, Cohen J, Sullivan R, Johnson D, Funchain P, Shoushtari A

  • J Immunother Cancer. 2020 Jun;8(1). pii: jitc-2019-000331. doi: 10.1136/jitc-2019-000331.
Open Access button

2020-07-14

Figure 2. Fraction genome altered, the proportion of genes with copy number alterations and a consequence of genomic instability, is compared by clinical phenotypes (with unadjusted mean group difference and 95% CI).

Figure 2. Fraction genome altered, the proportion of genes with copy number alterations and a consequence of genomic instability, is compared by clinical phenotypes (with unadjusted mean group difference and 95% CI).
  • Stopsack KH, Nandakumar S, Wibmer AG, Haywood S, Weg ES, Barnett ES, Kim CJ, Carbone EA, Vasselman SE, Nguyen B, Hullings MA, Scher HI, Morris MJ, Solit DB, Schultz N, Kantoff PW, Abida W

  • Clin Cancer Res. 2020 Jul 1;26(13):3230-3238.
Open Access button

2020-07-15

Figure 3.Favorable response to repotrectinib in ROS1-TKI treatment-naïve and ceritinib-resistant patients.

Figure 3.Favorable response to repotrectinib in ROS1-TKI treatment-naïve and ceritinib-resistant patients.
  • Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, Park CW, Heo SG, Kang HN, Lee SS, Schoenfeld AJ, Drilon A, Kang SG, Shim HS, Hong MH, Cui JJ, Kim HR, Cho BC

  • Clin Cancer Res. 2020 Jul 1;26(13):3287-3295.

2020-07-16

Graphical Abstract.

Graphical Abstract.
  • Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, Petralia F, ... Carr SA

  • Cell. 2020 Jul 9;182(1):200-225.e35.

2020-07-17

Fig. 1. Biodistribution of [225Ac]hu11B6.

Fig. 1. Biodistribution of [225Ac]hu11B6.
  • Bicak M, Luckerath K, Kalidindi T, Phelps ME, Strand SE, Morris MJ, Radu CG, Damoiseaux R, Peltola MT, Peekhaus N, Ho A, Veach D, Malmborg Hager AC, Larson SM, Lilja H, McDevitt MR, Klein RJ, Ulmert D

  • Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15172-15181. doi: 10.1073/pnas.1918744117. Epub 2020 Jun 12.

2020-07-20

Fig. 2: Low-dose AET inhibits migration of monocytic MDSCs from the bone marrow to the lung premetastatic microenvironment by downregulating expression of CCR2.

Fig. 2: Low-dose AET inhibits migration of monocytic MDSCs from the bone marrow to the lung premetastatic microenvironment by downregulating expression of CCR2.
  • Lu Z, Zou J, Li S, Topper MJ, Tao Y, Zhang H, Jiao X, Xie W, Kong X, Vaz M, Li H, Cai Y, Xia L, Huang P, Rodgers K, Lee B, Riemer JB, Day CP, Yen RC, Cui Y, Wang Y, Wang Y, Zhang W, Easwaran H, Hulbert A, Kim K, Juergens RA, Yang SC, Battafarano RJ, Bush EL, Broderick SR, Cattaneo SM, Brahmer JR, Rudin CM, Wrangle J, Mei Y, Kim YJ, Zhang B, Wang KK, Forde PM, Margolick JB, Nelkin BD, Zahnow CA, Pardoll DM, Housseau F, Baylin SB, Shen L, Brock MV

  • Nature. 2020 Mar;579(7798):284-290.

2020-07-21

Figure 1. Germline mutations in patients with Lynch syndrome.

Figure 1. Germline mutations in patients with Lynch syndrome.
  • Cercek A, Dos Santos Fernandes G, Roxburgh CS, Ganesh K, Ng S, Sanchez-Vega F, Yaeger R, Segal NH, Reidy-Lagunes DL, Varghese AM, Markowitz A, Wu C, Szeglin B, Sauve CG, Salo-Mullen E, Tran C, Patel Z, Krishnan A, Tkachuk K, Nash GM, Guillem J, Paty PB, Shia J, Schultz N, Garcia-Aguilar J, Diaz LA, Goodman K, Saltz LB, Weiser MR, Smith JJ, Stadler ZK

  • Clin Cancer Res. 2020 Jul 1;26(13):3271-3279.
Open Access button

2020-07-22

Graphical Abstract

Graphical Abstract
  • Mesin L, Schiepers A, Ersching J, Barbulescu A, Cavazzoni CB, Angelini A, Okada T, Kurosaki T, Victora GD

  • Cell. 2020 Jan 9;180(1):92-106.e11.
Open Access button

2020-07-23

Fig. 1 Maximum severity (A) and reversibility (B) of treatment-emergent adverse events (AEs) leading to permanent discontinuation.

Fig. 1 Maximum severity (A) and reversibility (B) of treatment-emergent adverse events (AEs) leading to permanent discontinuation.
  • Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A

  • Ann Oncol. 2018 Oct 1;29(10):2098-2104.
Open Access button

2020-07-24

Fig 2. ROC and precision-recall curves for the best models

Fig 2. ROC and precision-recall curves for the best models
  • Clark RA, Mostoufi-Moab S, Yasui Y, Vu NK, Sklar CA, Motan T, Brooke RJ, Gibson TM, Oeffinger KC, Howell RM, Smith SA, Lu Z, Robison LL, Chemaitilly W, Hudson MM, Armstrong GT, Nathan PC, Yuan Y

  • Lancet Oncol. 2020 Mar;21(3):436-445.

2020-07-27

Figure 1. Analysis of AR-FL and AR-Vs in prostate tissue (A-C) and CRPC blood samples (D-F).

Figure 1. Analysis of AR-FL and AR-Vs in prostate tissue (A-C) and CRPC blood samples (D-F).
  • Stuopelyte K, Sabaliauskaite R, Bakavicius A, Haflidadottir BS, Visakorpi T, Vaananen RM, Patel C, Danila DC, Lilja H, Lazutka JR, Ulys A, Jankevicius F, Jarmalaite S

  • J Urol. 2020 Jul;204(1):71-78. doi: 10.1097/JU.0000000000000803. Epub 2020 Feb 18.

2020-07-28

Fig. 2: Patient cohort and samples.

Fig. 2: Patient cohort and samples.
  • Landau HJ, Yellapantula V, Diamond BT, Rustad EH, Maclachlan KH, Gundem G, Medina-Martinez J, Ossa JA, Levine MF, Zhou Y, Kappagantula R, Baez P, Attiye M, Makohon-Moore A, Zhang L, Boyle EM, Ashby C, Blaney P, Patel M, Zhang Y, Dogan A, Chung DJ, Giralt S, Lahoud OB, Peled JU, Scordo M, Shah G, Hassoun H, Korde NS, Lesokhin AM, Lu S, Mailankody S, Shah U, Smith E, Hultcrantz ML, Ulaner GA, van Rhee F, Morgan GJ, Landgren O, Papaemmanuil E, Iacobuzio-Donahue C, Maura F

  • Nat Commun. 2020 Jul 17;11(1):3617. doi: 10.1038/s41467-020-17459-z.
Open Access button

2020-07-29

Fig. 1 Sparse CSF iron promotes LCN2 expression in cancer cells.

Fig. 1 Sparse CSF iron promotes LCN2 expression in cancer cells.
  • Chi Y, Remsik J, Kiseliovas V, Derderian C, Sener U, Alghader M, Saadeh F, Nikishina K, Bale T, Iacobuzio-Donahue C, Thomas T, Pe'er D, Mazutis L, Boire A

  • Science. 2020 Jul 17;369(6501):276-282. doi: 10.1126/science.aaz2193.

2020-07-30

Fig. 4 Increased Activation of Intratumoral CD8+ T cells in Patients Treated with Pegilodecakin.

Fig. 4 Increased Activation of Intratumoral CD8+ T cells in Patients Treated with Pegilodecakin.
  • Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M

  • Cancer Cell. 2018 Nov 12;34(5):775-791.e3.

2020-07-31

Figure 2. Progression-free survival.

Figure 2. Progression-free survival.
  • Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ

  • Lancet. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0.

2020-08-03

Fig 1. Incorporating telehealth and COVID‐19 precautions into cancer care during the pandemic: preflight checklist.

Fig 1. Incorporating telehealth and COVID‐19 precautions into cancer care during the pandemic: preflight checklist.
  • Kang JJ, Wong RJ, Sherman EJ, Rybkin A, McBride SM, Riaz N, Tsai CJ, Yu Y, Chen L, Zakeri K, Gelblum DY, Gillespie EF, Cohen MA, Cracchiolo JR, Ganly I, Patel S, Singh B, Boyle JO, Roman BR, Morris LG, Shaha AR, Dunn LA, Ho AL, Fetten JV, Shah JP, Pfister DG, Lee NY

  • Cancer. 2020 Jul 8:10.1002/cncr.33031.

2020-08-04

Fig 2. Various routes to leukemic transformation in MPNs.

Fig 2. Various routes to leukemic transformation in MPNs.
  • Dunbar AJ, Rampal RK, Levine R

  • Blood. 2020 Jul 2;136(1):61-70.

2020-08-05

Fig 2. Heatmap of candidate gene expressions with hierarchical clustering in PTCs (RPTECs) exposed to 6 different FLCs (T-κ1, T-κ2, T-κ3, T-λ1, T-λ2, T-λ3) for 24 hours.

Fig 2. Heatmap of candidate gene expressions with hierarchical clustering in PTCs (RPTECs) exposed to 6 different FLCs (T-κ1, T-κ2, T-κ3, T-λ1, T-λ2, T-λ3) for 24 hours.
  • Upadhyay R, Ying WZ, Nasrin Z, Safah H, Jaimes EA, Feng W, Sanders PW, Batuman V

  • JCI Insight. 2020 Jul 23;5(14). pii: 137191. doi: 10.1172/jci.insight.137191.

2020-08-06

Graphical Abstract

Graphical Abstract
  • Boissonnas A, Louboutin F, Laviron M, Loyher PL, Reboussin E, Barthelemy S, Reaux-Le Goazigo A, Lobsiger CS, Combadiere B, Melik Parsadaniantz S, Combadiere C

  • J Exp Med. 2020 Nov 2;217(11). pii: 151939. doi: 10.1084/jem.20200471.

2020-08-07

Graphical Abstract

Graphical Abstract
  • Balakrishnan M, Yu SF, Chin SM, Soffar DB, Windner SE, Goode BL, Baylies MK

  • Cell Rep. 2020 Jul 21;32(3):107893. doi: 10.1016/j.celrep.2020.107893.
Open Access button

2020-08-11

Fig 2. Chest CT demonstrates a right lower lobe mass with central low attenuation consistent with necrosis, a feature significantly associated with decreased out-of-field failure.

Fig 2. Chest CT demonstrates a right lower lobe mass with central low attenuation consistent with necrosis, a feature significantly associated with decreased out-of-field failure.
  • Plodkowski AJ, Araujo-Filho JAB, Simmers CDA, Girshman J, Raj M, Zheng J, Rimner A, Ginsberg MS

  • Clin Imaging. 2020 Jul 17;69:133-138. doi: 10.1016/j.clinimag.2020.07.005.

2020-08-12

Figure 1. TET2KO Cells Are More Stem-like than TET2WT Isogenic Counterparts.

Figure 1. TET2KO Cells Are More Stem-like than TET2WT Isogenic Counterparts.
  • Morinishi L, Kochanowski K, Levine RL, Wu LF, Altschuler SJ

  • Cell Syst. 2020 Jul 22;11(1):86-94.e5. doi: 10.1016/j.cels.2020.06.003. Epub 2020 Jul 2.
Open Access button

2020-08-13

Fig 6. SOAT1 abrogates cholesterol feedback inhibition to promote mevalonate pathway dependency in PDAC.

Fig 6. SOAT1 abrogates cholesterol feedback inhibition to promote mevalonate pathway dependency in PDAC.
  • Oni TE, Biffi G, Baker LA, Hao Y, Tonelli C, Somerville TDD, Deschenes A, Belleau P, Hwang CI, Sanchez-Rivera FJ, Cox H, Brosnan E, Doshi A, Lumia RP, Khaledi K, Park Y, Trotman LC, Lowe SW, Krasnitz A, Vakoc CR, Tuveson DA

  • J Exp Med. 2020 Sep 7;217(9). pii: 151922. doi: 10.1084/jem.20192389.

2020-08-14

Figure 1 COVID‐19 infection and immunotherapy for individual patients.

Figure 1 COVID‐19 infection and immunotherapy for individual patients.
  • Lara OD, O'Cearbhaill RE, Smith MJ, Sutter ME, Knisely A, McEachron J, Gabor LR, Jee J, Fehniger JE, Lee YC, Isani SS, Wright JD, Pothuri B

  • Cancer. 2020 Jul 30. doi: 10.1002/cncr.33084.

2020-08-17

Fig. 1. Best change in tumor size and characteristics in RECIST efficacy evaluable patients (N = 12).

Fig. 1. Best change in tumor size and characteristics in RECIST efficacy evaluable patients (N = 12).
  • Oaknin A, Friedman CF, Roman LD, D'Souza A, Brana I, Bidard FC, Goldman J, Alvarez EA, Boni V, ElNaggar AC, Passalacqua R, Do KTM, Santin AD, Keyvanjah K, Xu F, Eli LD, Lalani AS, Bryce RP, Hyman DM, Meric-Bernstam F, Solit DB, Monk BJ

  • Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)33660-X. doi: 10.1016/j.ygyno.2020.07.025.
Open Access button

2020-08-18

Graphical Abstract

Graphical Abstract
  • Escobar-Hoyos LF, Penson A, Kannan R, Cho H, Pan CH, Singh RK, Apken LH, Hobbs GA, Luo R, Lecomte N, Babu S, Pan FC, Alonso-Curbelo D, Morris JP 4th, Askan G, Grbovic-Huezo O, Ogrodowski P, Bermeo J, Saglimbeni J, Cruz CD, Ho YJ, Lawrence SA, Melchor JP, Goda GA, Bai K, Pastore A, Hogg SJ, Raghavan S, Bailey P, Chang DK, Biankin A, Shroyer KR, Wolpin BM, Aguirre AJ, Ventura A, Taylor B, Der CJ, Dominguez D, Kummel D, Oeckinghaus A, Lowe SW, Bradley RK, Abdel-Wahab O, Leach SD

  • Cancer Cell. 2020 Aug 10;38(2):198-211.e8.

2020-08-19

Figure: Correlations Between City Variables and Parking Costs

Figure: Correlations Between City Variables and Parking Costs
  • Lee A, Shah K, Chino F

  • JAMA Oncol. 2020 Jul 16. pii: 2768017. doi: 10.1001/jamaoncol.2020.1475.

2020-08-20

FIGURE 3.True-negative and false-positive PLG.

FIGURE 3.True-negative and false-positive PLG.
  • Mueller JJ, Dauer LT, Murali R, Iasonos A, Pandit-Taskar N, Abu-Rustum NR, Grimm J

  • J Nucl Med. 2020 Aug;61(8):1123-1130.

2020-08-21

Fig. 2. Immunohistochemical analysis of complement deposition in normal-appearing deltoid skin biopsies of three severe COVID-19 patients.

Fig. 2. Immunohistochemical analysis of complement deposition in normal-appearing deltoid skin biopsies of three severe COVID-19 patients.
  • Laurence J, Mulvey JJ, Seshadri M, Racanelli A, Harp J, Schenck EJ, Zappetti D, Horn EM, Magro CM

  • Clin Immunol. 2020 Aug 6;219:108555.

2020-08-24

Graphical Abstract.

Graphical Abstract.
  • Marjanovic ND, Hofree M, Chan JE, Canner D, Wu K, Trakala M, Hartmann GG, Smith OC, Kim JY, Evans KV, Hudson A, Ashenberg O, Porter CBM, Bejnood A, Subramanian A, Pitter K, Yan Y, Delorey T, Phillips DR, Shah N, Chaudhary O, Tsankov A, Hollmann T, Rekhtman N, Massion PP, Poirier JT, Mazutis L, Li R, Lee JH, Amon A, Rudin CM, Jacks T, Regev A, Tammela T

  • Cancer Cell. 2020 Aug 10;38(2):229-246.e13.

2020-08-25

Figure 1. Which ED patients benefit from the palliative approach?

Figure 1. Which ED patients benefit from the palliative approach?
  • Berta M, Leon A, Silvey K

  • Adv Emerg Nurs J. 2020 Jul/Sep;42(3):215-224. doi: 10.1097/TME.0000000000000307.

2020-08-26

Fig 1. Schematic of the five levels of epigenomics that drive transcriptional programmes in sarcomas.

Fig 1. Schematic of the five levels of epigenomics that drive transcriptional programmes in sarcomas.
  • Nacev BA, Jones KB, Intlekofer AM, Yu JSE, Allis CD, Tap WD, Ladanyi M, Nielsen TO

  • Nat Rev Cancer. 2020 Aug 11.

2020-08-27

Fig. 1. Histopathology: clear cell RCC.

Fig. 1. Histopathology: clear cell RCC.
  • Gupta S, Vanderbilt CM, Leibovich BC, Herrera-Hernandez L, Raghunathan A, Sukov WR, Voss JS, Barr Fritcher EG, Reed KA, Lohse CM, Reuter VE, Jimenez RE, Thompson RH, Cheville JC

  • Hum Pathol. 2020 Jul 15;103:1-13.

2020-08-28

Graphical Abstract

Graphical Abstract
  • Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, ... Lyden D.

  • Cell. 2020 Aug 20;182(4):1044-1061.e18.

2020-08-31

Figure 8. Two components of DNA replication-dependent LexA cleavage.

Figure 8. Two components of DNA replication-dependent LexA cleavage.
  • Myka KK, Marians KJ

  • J Biol Chem. 2020 Jul 24;295(30):10368-10379. doi: 10.1074/jbc.RA120.014224. Epub 2020 Jun 8.
Open Access button

2020-09-01

Fig 2. Suggested infection prevention practices for bone marrow transplant units.

Fig 2. Suggested infection prevention practices for bone marrow transplant units.
  • Waghmare A, Abidi MZ, Boeckh M, Chemaly RF, Dadwal S, El Boghdadly Z, Kamboj M, Papanicolaou GA, Pergam SA, Shahid Z

  • Biol Blood Marrow Transplant. 2020 Jul 28:S1083-8791(20)30460-2
Open Access button

2020-09-02

Fig. 2. Histologic features of resection specimen.

Fig. 2. Histologic features of resection specimen.
  • Hagen CE, Christians K, Hopp A, Giorgadze T, Hartley CP, Hunt B, Basturk O, Klimstra D

  • Ann Diagn Pathol. 2020 Aug 13;48:151583. doi: 10.1016/j.anndiagpath.2020.151583.

2020-09-03

Fig 2. TXNIP suppression is PGD-dependent.

Fig 2. TXNIP suppression is PGD-dependent.
  • Bechard ME, Smalling R, Hayashi A, Zhong Y, Word AE, Campbell SL, Tran AV, Weiss VL, Iacobuzio-Donahue C, Wellen KE, McDonald OG

  • Nat Commun. 2020 Aug 13;11(1):4055.
Open Access button

2020-09-04

Fig 1. An active IDO/TDO-Kyn-AHR pathway associates with immune suppressive features in human cancers.

Fig 1. An active IDO/TDO-Kyn-AHR pathway associates with immune suppressive features in human cancers.
  • Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, Redmond D, Mangarin L, Pourpe S, Liu C, Zappasodi R, Zamarin D, Cavanaugh J, Castro AC, Manfredi MG, McGovern K, Merghoub T, Wolchok JD

  • Nat Commun. 2020 Aug 11;11(1):4011.
Open Access button

2020-09-08

FIGURE 5. Changes in knowledge.

FIGURE 5. Changes in knowledge.
  • O'Shea D, Fischer-Cartlidge E

  • Clin Nurse Spec. 2020 Sep/Oct;34(5):217-221. doi: 10.1097/NUR.0000000000000544.

2020-09-09

Visual Abstract

Visual Abstract
  • Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, Gill SI, Manning BM, Koprivnikar J, McCloskey J, Testi R, Prebet T, Al Ali NH, Padron E, Sallman DA, Komrokji RS, Goldberg AD

  • Blood Adv. 2020 Jul 14;4(13):2866-2870. doi: 10.1182/bloodadvances.2020001482.
Open Access button

2020-09-10

Fig 2. CRISPR/Cas9 mediated gene editing.

Fig 2. CRISPR/Cas9 mediated gene editing.
  • Uddin F, Rudin CM, Sen T

  • Front Oncol. 2020 Aug 7;10:1387. doi: 10.3389/fonc.2020.01387. eCollection 2020.
Open Access button

2020-09-11

Fig 4. Pairs of features in predictive models.

Fig 4. Pairs of features in predictive models.
  • von Reibnitz D, Yorke ED, Oh JH, Apte AP, Yang J, Pham H, Thor M, Wu AJ, Fleisher M, Gelb E, Deasy JO, Rimner A

  • Front Oncol. 2020 Aug 6;10:1395. doi: 10.3389/fonc.2020.01395. eCollection 2020.
Open Access button

2020-09-14

Fig 4. MSI proteins in hippocampus and cortex of P301L tau mouse model.

Fig 4. MSI proteins in hippocampus and cortex of P301L tau mouse model.
  • Montalbano M, McAllen S, Puangmalai N, Sengupta U, Bhatt N, Johnson OD, Kharas MG, Kayed R

  • Nat Commun. 2020 Aug 27;11(1):4305. doi: 10.1038/s41467-020-18022-6.
Open Access button

2020-09-15

Figure 2. Schematic capturing our current general approach for relapsed or refractory patients with AML with some factors guiding the clinical decision process.

Figure 2. Schematic capturing our current general approach for relapsed or refractory patients with AML with some factors guiding the clinical decision process.
  • DeWolf S, Tallman MS

  • Blood. 2020 Aug 27;136(9):1023-1032. doi: 10.1182/blood.2019001982.

2020-09-16

Fig 1. The American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading and recommended management for cytokine release syndrome (CRS) and neurological toxicity associated with immune effector cells (ICANS). DXM, Dexamethasone; ICE, immune effector cell-associated encephalopathy; ICU, intensive care unit; MP, Methylprednisolone.

Fig 1. The American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading and recommended management for cytokine release syndrome (CRS) and neurological toxicity associated with immune effector cells (ICANS). DXM, Dexamethasone; ICE, immune effector cell-associated encephalopathy; ICU, intensive care unit; MP, Methylprednisolone.
  • Yanez L, Alarcon A, Sanchez-Escamilla M, Perales MA

  • ESMO Open. 2020 Aug;4(Suppl 4). pii: esmoopen-2020-000746. doi: 10.1136/esmoopen-2020-000746.
Open Access button

2020-09-17

Fig 1..Scheme for chemotherapy induced ceramide-rich microdomains (CRM = CRP ceramide-rich platforms) generation.

Fig 1..Scheme for chemotherapy induced ceramide-rich microdomains (CRM = CRP ceramide-rich platforms) generation.
  • Nepali PR, Haimovitz-Friedman A

  • Methods Mol Biol. 2021;2187:215-221. doi: 10.1007/978-1-0716-0814-2_12.

2020-09-18

Figure 1: Services provided by our lay navigation staff, which encompassed managing medical and treatment, financial, and psychosocial barriers to the timely completion of treatment.

Figure 1: Services provided by our lay navigation staff, which encompassed managing medical and treatment, financial, and psychosocial barriers to the timely completion of treatment.
  • Dessources K, Hari A, Pineda E, Amneus MW, Sinno AK, Holschneider CH

  • Cancer. 2020 Sep 5. doi: 10.1002/cncr.33124.

2020-09-21

Figure 1: Examples of CD19 (a) and CD40 (b)‐dependent gating are shown.

Figure 1: Examples of CD19 (a) and CD40 (b)‐dependent gating are shown.
  • Jennifer GM, Gao Q, Wardrope J, Dogan A, Roshal M

  • Cytometry B Clin Cytom. 2020 Sep 8. doi: 10.1002/cyto.b.21953.

2020-09-22

Fig. 1. The origins of clonal hematopoiesis (CH) detected in allogeneic hematopoietic cell transplantation (allo-HCT) recipients post-transplant.

Fig. 1. The origins of clonal hematopoiesis (CH) detected in allogeneic hematopoietic cell transplantation (allo-HCT) recipients post-transplant.
  • Nawas MT, Schetelig J, Damm F, Levine RL, Angel-Perales M, Giralt SA, VanDenBrink MR, Arcila ME, Zehir A, Papaemmanuil E, Klussmeier A, Schmidt AH, Maiwald S, Bolton KL, Tamari R

  • Blood Rev. 2020 Aug 24:100744. doi: 10.1016/j.blre.2020.100744.

2020-09-23

Fig. 1. Morphologic spectrum of SMARCB1-deficient SNCs.

Fig. 1. Morphologic spectrum of SMARCB1-deficient SNCs.
  • Dogan S, Cotzia P, Ptashkin RN, Nanjangud GJ, Xu B, Momeni Boroujeni A, Cohen MA, Pfister DG, Prasad ML, Antonescu CR, Chen Y, Gounder MM

  • Hum Pathol. 2020 Aug 18;104:105-116.

2020-09-24

Fig. 2. p53 immunohistochemical expression patterns and correlation with TP53 mutation status in high grade urothelial carcinoma of the bladder.

Fig. 2. p53 immunohistochemical expression patterns and correlation with TP53 mutation status in high grade urothelial carcinoma of the bladder.
  • Hodgson A, van Rhijn BWG, Kim SS, Ding C, Saleeb R, Vesprini D, Liu SK, Yousef GM, van der Kwast TH, Xu B, Downes MR

  • Pathol Res Pract. 2020 Aug 23;216(11):153186. doi: 10.1016/j.prp.2020.153186.

2020-09-25

Fig. 2. Computational strategy and description of driver co-occurrence (DCO) networks.

Fig. 2. Computational strategy and description of driver co-occurrence (DCO) networks.
  • Mateo L, Duran-Frigola M, Gris-Oliver A, Palafox M, Scaltriti M, Razavi P, Chandarlapaty S, Arribas J, Bellet M, Serra V, Aloy P

  • Genome Med. 2020 Sep 9;12(1):78.
Open Access button

2020-09-28

Fig. 1. Patterns of pan-Trk immunohistochemistry expression in NTRK fusion positive cancers.

Fig. 1. Patterns of pan-Trk immunohistochemistry expression in NTRK fusion positive cancers.
  • Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, Hyman DM, Ladanyi M, Sireci AN, Hechtman JF

  • Mod Pathol. 2020 Jan;33(1):38-46.

2020-09-30

Fig. 4: Cytogenetic and molecular features of locally advanced/metastatic mucinous tubular and spindle cell carcinoma.

Fig. 4: Cytogenetic and molecular features of locally advanced/metastatic mucinous tubular and spindle cell carcinoma.
  • Yang C, Cimera RS, Aryeequaye R, Jayakumaran G, Sarungbam J, Al-Ahmadie HA, Gopalan A, Sirintrapun SJ, Fine SW, Tickoo SK, Epstein JI, Reuter VE, Zhang Y, Chen YB

  • Mod Pathol. 2020 Sep 2. pii: 10.1038/s41379-020-00667-9. doi: 10.1038/s41379-020-00667-9.

2020-10-01

Fig 1. Exercise-induced protection against tissue-specific perturbations in organs involved in cancer regulation or prone to malignancy.

Fig 1. Exercise-induced protection against tissue-specific perturbations in organs involved in cancer regulation or prone to malignancy.
  • Koelwyn GJ, Zhuang X, Tammela T, Schietinger A, Jones LW

  • Nat Metab. 2020 Sep;2(9):849-857.